UniQure Soars 75% After FDA Backs Huntington's Gene Therapy Filing Plan
Updated
Updated · CNBC · Jun 17
UniQure Soars 75% After FDA Backs Huntington's Gene Therapy Filing Plan
3 articles · Updated · CNBC · Jun 17
Summary
UniQure shares jumped nearly 75% Wednesday after the Dutch biotech said the FDA agreed with its plan to submit an application for a Huntington's disease gene therapy.
That regulatory alignment signaled a clearer path toward a formal filing, making UniQure one of the biggest midday movers in U.S. trading.
The surge stood out in a session marked by sharp stock-specific moves, including La-Z-Boy up 19%, SharonAI up nearly 15% and CarMax down 7%.
For UniQure, the FDA's feedback is the key near-term catalyst because Huntington's disease remains a high-need neurodegenerative market with limited treatment options.